Connect Biopharma is trading at $2.65 (up 5.4%) as the stock rebounds from a minor pullback, supported by a wave of bullish analyst sentiment.
- Oppenheimer recently initiated coverage on the stock with an Outperform rating and an $8 price target, contributing to a broader "Strong Buy" consensus among Wall Street analysts.
- The current upward move follows a 5.6% consolidation on July 10, which came after a significant 19.8% rally on July 9 sparked by fresh analyst enthusiasm.
- Investors continue to react positively to the significant upside potential implied by recent price targets compared to the current trading range.